Skip to content
Friday, October 23, 2026 · Today’s edition, 6:30 a.m. ETFri, Oct 23 · 6:30 a.m. editionSign inMy Desk 0EditionsSign in

T. Rowe Price's TMED makes the case for active sector ETFs

A 44-basis-point fee and a bottom-up, global mandate are beating the S&P health-care benchmark by wide margins.

At a glance

  1. The fund charges 44 basis points and holds between 100 and 150 health-care stocks from around the world.
  2. TMED's process is deliberately broad.
  3. TMED is becoming a useful test case for active sector ETFs.

TMED, the T. Rowe Price Health Care ETF, is an argument for active management inside a sector fund. The fund charges 44 basis points and holds between 100 and 150 health-care stocks from around the world. It has returned about 19% so far this year. Its 12-month return is 49.1%, according to ETF Database data. The S&P Health Care Select Sector Index is up 8% year to date. Over the same 12 months, the index has gained 28.2%, T. Rowe Price says. ETF Trends reported the comparison.

TMED's process is deliberately broad. A bottom-up approach blends growth and value analysis across pharmaceuticals, biotech, and health-care services. Most of the fund sits inside the MSCI GICS health-care sector. The ETF wrapper adds transparency, flexibility, and tax efficiency — the same qualities that made sector funds a default vehicle. But the active remit separates this fund from the passive crowd. Many passive sector ETFs hold small, specialized indexes that can be volatile; broader passive baskets absorb the swings of the whole group. A manager with a mandate to range across the sector can skip the weakest companies and follow the strongest ideas where they lead.

TMED is becoming a useful test case for active sector ETFs. Its performance suggests a manager working company by company can beat the sector index without tying the fund to a narrow theme. The fund also arrives as active strategies gather momentum. ETF Daily's coverage has tracked $272.5 billion in active stock-fund inflows this year. Goldman Sachs has agreed to acquire NEOS, the $30 billion options-income issuer. In a portfolio, these funds are best treated as satellites, not cores — a way to express a sector view while handing stock selection to a manager.

Competitors face a process problem, not a packaging problem. Any issuer can put a health-care label on an active wrapper. The hard part is the research conviction that lets a manager range across a broad sector and still beat the index. TMED's numbers offer a template — and a target.

TMED vs. S&P Health Care Index Returns

  • TMED 12-mo49.1%
  • Index 12-mo28.2%
  • TMED YTD19%
  • Index YTD8%
Source: ETF Database data via ETF Trends; T. Rowe Price
Show as table
ItemValue (%)
TMED YTD19%
Index YTD8%
TMED 12-mo49.1%
Index 12-mo28.2%

TMED vs. S&P Health Care Index Returns

  • TMED 12-mo49.1%
  • Index 12-mo28.2%
  • TMED YTD19%
  • Index YTD8%
Source: ETF Database data via ETF Trends; T. Rowe Price
Show as table
ItemValue (%)
TMED YTD19%
Index YTD8%
TMED 12-mo49.1%
Index 12-mo28.2%

TMED vs. S&P Health Care Index Returns

  • TMED 12-mo49.1%
  • Index 12-mo28.2%
  • TMED YTD19%
  • Index YTD8%
Source: ETF Database data via ETF Trends; T. Rowe Price
Show as table
ItemValue (%)
TMED YTD19%
Index YTD8%
TMED 12-mo49.1%
Index 12-mo28.2%

Reported by the Active desk from ETF Trends and ETF Daily. Published . Corrections

Related

ETFs

Three August ETF deals price a book of advisor relationships

August's three ETF acquisitions priced the scarce asset—a book of advisor relationships—and the next wave will be issuers who own one and cannot sell it.

ETFs

T. Rowe Price's crypto ETF tests whether a research fee travels

TKNZ's 75 basis points only work if its managers beat a basket an advisor could buy, and that is the one part of the launch T. Rowe Price has not shown.

ETFs

Active ETFs' durable pitch is tax and trading mechanics

Short-duration active bond funds get sold as all-weather answers to the Fed, which is precisely where a management fee has the least to come out of.

ETFs

PRIMECAP plans Wednesday launch of first ETF, POMG, at 0.68%

The PRIMECAP Odyssey Discovery ETF will trade on NYSE Arca and aims to beat the Russell Midcap Growth Index over three to five years, per its prospectus.

ETFs

Fidelity's FYEE fund reports a 9.1% trailing yield against a 6-8% payout target

Since inception, the fund held an equity beta of roughly 0.79 and captured about 80% to 85% of the S&P 500's cumulative return, according to Fidelity portfolio manager Eric Granat.

ETF Dailyfrom Private Wealth Daily

Flows, launches, fee moves and the funds advisors are adding to models. Weekdays at 6:55 a.m. ET.

Free. Weekday mornings. Unsubscribe from any edition in one click.

From other sections